



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 6, 2022

Justin De Four  
Chief Executive Officer  
BioLife Sciences Inc.  
2831 St. Rose Parkway #200  
Henderson, NV 89052

**Re: BioLife Sciences Inc.**  
**Offering Statement on Form 1-A**  
**Filed May 31, 2022**  
**File No. 024-11898**

Dear Mr. De Four:

This is to advise you that we do not intend to review your offering statement.

We will consider qualifying your offering statement at your request. In connection with your request, please confirm in writing that at least one state has advised you that it is prepared to qualify or register your offering. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Jonathan Leinwand, Esq.